Beyond Biotech - the podcast from Labiotech
Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday.The host is Jim Cornall.
Episodes
114 episodes since 2022
Targeting inflammation: A revolution in disease treatment
Inflammation appears to affect almost every part of the human body as we age, including cancer, type-2 diabetes, obesity, and neurodegenerative disorders.NLRP3 inflammasome-induced inflammation is at the root of nearly all disease...
September 13, 2024
•
43:10
The power of tumor infiltrating lymphocytes to fight melanoma
Tumor infiltrating lymphocyte (TIL) therapy uses a person’s own immune cells to fight advanced melanoma, offering new hope for patients who have limited treatment options. This week, we have a conversation with Brian Gastman,...
September 06, 2024
•
38:03
The future of combination vaccines
The development of combination vaccines could represent a significant advancement in the fight against infectious diseases. With the potential to streamline the vaccination process and provide broader protection, these vaccines could greatly im...
August 30, 2024
•
24:44
New German biotech spins out to develop radiotherapeutics
Pentixapharm is a clinical-stage radiopharmaceutical development company targeting a range of diseases. While it is currently owned by the Eckert & Ziegler Group, it will soon be spun off as a separate company. Pentixapharm’s cl...
August 23, 2024
•
18:35
Challenging the European biotech funding status quo
There are many questions when it comes to setting up a biotech company, and raising funds. Currently, many companies are concerned about fundraising, but there are things that can be done to maximize efforts. Does a company’s loc...
August 16, 2024
•
36:36
[Rebroadcast] Epigenetic editing – the power of CRISPR without cutting DNA
While our podcast takes a brief break, Labiotech invites you to enjoy some of our favorite episodes. We will return with a brand-new episode on August 16, 2024! Have an awesome summer!Epic Bio is an epigenetic editing company, levera...
August 09, 2024
•
32:57
[Rebroadcast] How does AI assist drug discovery?
While our podcast takes a brief break, Labiotech invites you to enjoy some of our favorite episodes. We will return with a brand-new episode on August 16, 2024! Have an awesome summer!Artificial intelligence (AI) is certainly in the ...
August 02, 2024
•
38:40
The first mass-market cell therapy?
Aurion Biotech is a US biotech with a regenerative medicine platform, developing novel therapies to restore vision to millions of people in need. This week on the podcast, we have a conversation with CEO Greg Kunst about Auri...
July 26, 2024
•
25:34
Cutting through the AI hype in drug discovery
LabGenius is a drug discovery company developing next-generation therapeutic antibodies. The company’s discovery platform, EVA, integrates several technologies drawn from the fields of artificial intelligence (AI), robotic a...
July 19, 2024
•
26:13
How biotechs are revolutionizing acute on-chronic liver failure?
Acute on-chronic liver failure (ACLF) is a significant healthcare issue with high unmet needs for patients and clinicians, and a massive burden for healthcare systems. It cost more than $6bn in the US alone in 2021, with a drastic increase o...
July 12, 2024
•
29:22
The radiotherapeutics boom
The field of radiotherapeutics is a hot topic currently, and so who better to talk about the subject than Ken Herrmann, a radiopharmaceutical academic expert, who is Professor of Nuclear Medicine at the Universitätsklinikum Essen, in Essen Germ...
July 05, 2024
•
39:43
Priovant - finding options to treat autoimmune diseases
US-based biotech company Priovant Therapeutics is dedicated to developing novel therapies for autoimmune diseases with high morbidity and few available treatment options. The company's lead asset, brepocitinib, is a dual sele...
June 28, 2024
•
30:05
How ADCs can deliver death cap mushroom toxins to treat cancer
Heidelberg Pharma is a clinical stage biotech company developing antibody drug conjugates (ADCs).Its lead amanitin-based ADC product candidate, HDP-101, targets relapsed or refractory multiple myeloma. HDP-101 recently received or...
June 21, 2024
•
28:09
Looking to cure Type 1 diabetes
Diamyd Medical develops precision medicine therapies for the prevention and treatment of Type 1 diabetes and LADA (latent autoimmune diabetes in adults). Diamyd is an antigen-specific immunomodulatory therapeutic for the pres...
June 14, 2024
•
23:40
Developing treatments for rare pediatric diseases
Rare diseases affect around 1 in 2,000 people. Many of the thousands of rare diseases are difficult to diagnose. Of the known rare diseases, about 80% have genetic causes. Leukodystrophies are a group of rare genetic disorders for ...
June 07, 2024
•
29:17
Can cell therapy tackle hearing loss?
Hearing loss is a huge – and growing – global challenge.Using its OSPREY platform, UK-based Rinri Therapeutics is developing a portfolio of off-the-shelf regenerative cell therapy products to address sensorineural hearing loss, a ...
May 31, 2024
•
31:00
How biotech is tackling myasthenia gravis
June is myasthenia gravis awareness month. Myasthenia gravis is a chronic autoimmune disorder where antibodies destroy the communication between nerves and muscle, and this results in weakness of the skeletal muscles. It espe...
May 24, 2024
•
28:50
Antisense oligonucleotides
German-headquartered Isarna Therapeutics is developing a portfolio of antisense therapies targeting an emerging therapeutic field in human biology – transforming growth factor beta (TGF-B) signaling. Precise modulation of TGF-B p...
May 17, 2024
•
27:22
Making waves in cardiovascular disease treatment
Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilita...
May 10, 2024
•
21:02
New ways to treat Duchenne muscular dystrophy
Duchenne muscular dystrophy (DMD) is a genetic disorder with progressive muscle degeneration and weakness due to changes in the protein dystrophin, which helps keep muscle cells intact. There are few treatments for DMD, altho...
May 03, 2024
•
23:56
Overcoming clinical trial challenges
This week, we have a conversation about clinical trial design with Gen Li, the president and founder of Phesi, a global provider of patient-centric data analysis. Earlier this year, Phesi’s global analysis of all clinical tri...
April 26, 2024
•
26:00
The biotech investment landscape in 2024
RTW is a global multi-strategy investment firm focused on supporting innovative biotech and biopharma companies across the US, Europe, and China. The company invests in both public and private companies across their entire li...
April 19, 2024
•
28:32
Redefining chronic pain treatment
Doloromics is a precision neuropharmaceuticals company. It was set up four years ago, to use newer technologies, particularly in the omics space, to take advantage of different single-cell transcriptomic technologies or proteomic technologie...
April 12, 2024
•
35:42
Colossal aims to bring back mammoth by 2028
Based in Austin, Texas, biotech Colossal Biosciences is at the forefront of de-extinction, critically endangered species protection and the repopulation of critical ecosystems. Its mission is to use CRISPR technology to bring...
April 05, 2024
•
38:24
New treatments being developed for schizophrenia
It would appear that 2024 is shaping up to be a big year for the development of treatments for schizophrenia, with several clinical trials under way.Recently, Boehringer Ingelheim and Sosei Group Corporation (Sosei Heptares) annou...
March 22, 2024
•
25:31